[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jean Seely\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100630698","wide-angle-tomosynthesis-and-ai-in-diagnostic-mammography-100630698",false,"NCT07491055","Wide-Angle Tomosynthesis and AI in Diagnostic Mammography","Evaluation of Wide-Angle Tomosynthesis and AI in Diagnostic Mammography at The Ottawa Hospital","Inclusion Criteria:\n\n* Provides verbal consent to participate.\n* Referred for diagnostic breast imaging at The Ottawa Hospital due to:\n* Recall from a screening mammogram for a soft-tissue lesion, or\n* Breast symptoms (e.g., palpable mass, nipple discharge) with last screening mammogram \\>6 months prior.\n* Able to undergo wide-angle DBT and Insight 2D views on the Siemens MAMMOMAT B.brilliant system.\n\nExclusion Criteria:\n\n* Presence of breast implants.\n* History of breast surgery on the breast being evaluated.\n* Required imaging views not obtained (wide-angle DBT + Insight 2D views).\n* Unable or unwilling to complete the imaging procedure per standard protocol.\n* Declines the use of AI on the mammography unit (patients who decline are imaged on another machine and not included).","FEMALE","18 Years",{"count":19,"type":20},1400,"ESTIMATED","OBSERVATIONAL","Breast cancer remains the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women globally. Timely and accurate detection is crucial for improving prognosis and survival outcomes. While digital mammography has long served as the gold standard for screening, it is limited by overlapping tissue structures, particularly in women with dense breasts, which can obscure malignancies or create false positives.\n\nTo address these limitations, digital breast tomosynthesis (DBT), especially wide-angle DBT, has been developed to offer three-dimensional imaging and reduce tissue overlap. Siemens' MAMMOMAT B.brilliant system, which incorporates wide-angle DBT, enhances spatial resolution and improves lesion conspicuity. This technology may offer significant benefits in diagnostic populations, where accuracy and confidence in imaging interpretation are crucial.\n\nIn parallel, artificial intelligence (AI) tools such as the Transpara system have been introduced to further improve mammographic interpretation. Previously the evaluation of Transpara in a sample of 310 Japanese women and found that while human readers outperformed AI in overall diagnostic performance, the system showed promising sensitivity levels, highlighting the potential of AI as a decision-support tool rather than a standalone reader.\n\nMore robust evidence is provided by the Mammography Screening with Artificial Intelligence (MASAI) trial, which assessed AI-supported screen reading in a controlled study of over 80,000 women. The trial found that AI-supported reading led to a comparable cancer detection rate as standard double reading (6.1 vs. 5.1 per 1000 participants) but reduced reading workload by 44.3% without increasing false positives or recall rates. A related analysis by the same team emphasized the capability of AI to triage exams effectively and highlighted that AI-flagged \"extra high risk\" mammograms accounted for a substantial portion (over 55%) of all screen-detected cancers, with a high positive predictive value.\n\nDespite these encouraging findings, most studies have been limited to screening-based settings. There remains a lack of prospective evidence on the real-world diagnostic application of wide-angle DBT and AI in populations at higher risk, such as symptomatic patients or those recalled from screening. This represents a critical knowledge gap, especially given increasing concerns about radiologist workload and diagnostic delays.\n\nThe purpose of this prospective observational study is to evaluate the integration and diagnostic value of wide-angle tomosynthesis and AI (Transpara) in a clinical diagnostic setting. Specifically, it aims to assess their influence on radiologist confidence, diagnostic accuracy and the need for supplementary imaging. By addressing these questions, the study seeks to inform future implementation strategies that balance accuracy, efficiency, and clinical utility.",[24,25],"Breast Neoplasms Diagnosis","Brest Cancer",[27,28,29,30,31,32,33,34,35],"Breast Cancer","Diagnostic Mammography","Digital Breast Tomosynthesis (DBT)","Wide-Angle Tomosynthesis","Artificial Intelligence","AI-Assisted Imaging","Transpara AI","Siemens MAMMOMAT B.brilliant","Breast Imaging","NOT_YET_RECRUITING","2026-03-19",{"date":39,"type":40},"2026-03-24","ACTUAL",{"date":42,"type":20},"2026-04-01",{"date":44,"type":20},"2029-12-31",{"name":46,"class":47},"Jean Seely","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100592424","contrast-enhanced-mammography-in-women-with-a-personal-history-of-breast-cancer-and-dense-breast-tissue-benefit-100592424","NCT06993246","Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit?","Does Supplemental Contrast-enhanced Mammography Have a Benefit in Women With a Personal History of Breast Cancer and Dense Breast Tissue? A Prospective Cohort Study.","CEM","Inclusion Criteria:\n\n* Women presenting at Rose Ages Breast Health Center, who are currently waiting for supplemental screening Ultrasound, according to pre-established guidelines at TOH for supplemental screening.\n* Women ages 50-69 years of age\n* Those willing to participate in the study, sign an informed consent and undergo IV iodinated contrast injection\n* Women with dense breasts (category C or D) and normal mammograms (BI-RADS 1 or 2)\n* No evidence of renal disease\n\nExclusion Criteria:\n\n* Patients with renal insufficiency (reduced eGFR \\\u003C20ml\u002Fmin)\n* Previous allergic reactions to Iodine-based contrast.\n* Prior contrast allergy (CT contrast)\n* Thyroid Disease","50 Years","69 Years",{"count":59,"type":20},50,"INTERVENTIONAL",[62],"NA","This study aims to assess the effectiveness of Contrast-Enhanced Mammography (CEM)as an alternative to traditional ultrasound for breast cancer screening in women with dense breasts and a personal history of breast cancer. CEM combines standard mammography with a contrast agent to better detect tumors, particularly in women with dense tissue where traditional mammograms may miss signs of cancer. The study will compare CEM with ultrasound and MRI to determine its accuracy in detecting cancer, reduce wait times for screening, and provide a more affordable option than MRI. Women who participate will have their screening done in one visit, improving convenience and access. The study will track cancer detection rates, biopsy results, and patient satisfaction over two years to evaluate the benefits of CEM for early breast cancer detection.",[27],[66,67,68],"Mammography screening","Contrast-Enhanced Mammography","Dense breasts","2025-05-23",{"date":71,"type":40},"2025-05-28",{"date":73,"type":20},"2025-09-15",{"date":75,"type":20},"2028-09-30",{"name":46,"class":47},1,""]